120 related articles for article (PubMed ID: 17851243)
21. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
22. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
23. [Only 1 injection per week brings a 60% chance of healing. New therapy recommendations in chronic hepatitis C].
Niederau C
MMW Fortschr Med; 2003 Jan; 145(1-2):28-32. PubMed ID: 12638435
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
26. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.
Stein MR; Soloway IJ; Jefferson KS; Roose RJ; Arnsten JH; Litwin AH
J Subst Abuse Treat; 2012 Dec; 43(4):424-32. PubMed ID: 23036920
[TBL] [Abstract][Full Text] [Related]
27. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?
Taylor LE; Maynard MA; Friedmann PD; Macleod CJ; Rich JD; Flanigan TP; Sylvestre DL
J Addict Med; 2012 Sep; 6(3):179-85. PubMed ID: 22614935
[TBL] [Abstract][Full Text] [Related]
28. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment.
Zickmund SL; Campbell SA; Tirado CF; Zook CL; Weinrieb RM
J Addict Med; 2012 Sep; 6(3):233-9. PubMed ID: 22790464
[TBL] [Abstract][Full Text] [Related]
29. Treating chronic hepatitis C in recovering opiate addicts: yes, we can.
Kreek MJ; Talal AH; Piccolo P
Dig Liver Dis; 2009 Apr; 41(4):308-10. PubMed ID: 19233749
[No Abstract] [Full Text] [Related]
30. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.
Ogbuagu O; Friedland G; Bruce RD
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):721-31. PubMed ID: 27140427
[TBL] [Abstract][Full Text] [Related]
31. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study.
Batki SL; Canfield KM; Smyth E; Ploutz-Snyder R; Levine RA
J Addict Dis; 2010 Jul; 29(3):359-69. PubMed ID: 20635285
[TBL] [Abstract][Full Text] [Related]
33. A model for treating HCV hepatitis in patients receiving methadone maintenance therapy.
Malnick S; Sheidvasser V; Basevitz A; Levit S
Isr J Psychiatry Relat Sci; 2014; 51(4):303-5. PubMed ID: 25841229
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
Carey KJ; Huang W; Linas BP; Tsui JI
J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
[TBL] [Abstract][Full Text] [Related]
35. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?
Guadagnino V; Trotta MP; Carioti J; Caroleo B; Antinori A;
Dig Liver Dis; 2006 Feb; 38(2):119-24. PubMed ID: 16297672
[TBL] [Abstract][Full Text] [Related]
36. Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.
Wittchen HU; Apelt SM; Bühringer G; Gastpar M; Backmund M; Gölz J; Kraus MR; Tretter F; Klotsche J; Siegert J; Pittrow D; Soyka M
Int J Methods Psychiatr Res; 2005; 14(1):14-28. PubMed ID: 16097397
[TBL] [Abstract][Full Text] [Related]
37. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study.
Greenwald MK; Schuh KJ; Stine SM
Am J Addict; 2003; 12(4):365-74. PubMed ID: 14504028
[TBL] [Abstract][Full Text] [Related]
38. Management of hepatitis C virus infections in intravenous drug users.
Robaeys G; Matheï C; Buntinx F; Vanranst M
Acta Gastroenterol Belg; 2002; 65(2):99-100. PubMed ID: 12148448
[TBL] [Abstract][Full Text] [Related]
39. Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma.
Kim SY; Cho SG; Kim SW; Choi BO; Park KS; Lim J; Min CK; Kim YG; Lee JW; Min WS
Ann Hematol; 2011 Jun; 90(6):693-9. PubMed ID: 21088967
[TBL] [Abstract][Full Text] [Related]
40. Depression Disorders in Patients with Chronic Hepatitis C.
Bebek-Ivankovic H; Bevanda M; Susak B; Grgic S; Soldo-Coric L; Nikolic J
Psychiatr Danub; 2020 Nov; 32(Suppl 4):540-546. PubMed ID: 33212461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
